Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clonal dissemination and plasmid plasticity of KPC-3-producing Klebsiella pneumoniae ST512 during a hospital outbreak in Spain

  • Riesgo-Magaña, María|||0000-0003-0825-9319
  • Moreno Mingorance, Albert|||0000-0002-3073-5046
  • Bueno, Jessica|||0000-0002-4125-8150
  • Arnal, Sara|||0000-0001-8889-6857
  • Alvarado, Elena|||0000-0003-3560-5096
  • González-López, Juanjo|||0000-0003-2419-5909
  • Seral, Cristina|||0000-0002-9742-1463
Purpose: To describe the first outbreak of KPC-3-producing Klebsiella pneumoniae ST512 in Aragón, Spain, and characterize its clinical, microbiological, and genomic features, including plasmid dynamics, resistance mechanisms, and phylogenetic context. Methods: Between July 2022 and July 2024, 130 KPC-3-producing K. pneumoniae isolates were recovered from 33 patients during an outbreak at a tertiary-care hospital in Zaragoza. Antimicrobial susceptibility testing and whole-genome sequencing were performed. Phylogenomic (SNP and cgMLST) and plasmid analyses defined clonal relatedness and plasmid structures. Comparative genomics with 985 international ST512/KPC-3 genomes determined phylogeographic relationships. Results: Most cases (84.6%) were detected through active surveillance. All the isolates were resistant to β-lactams, ceftolozane/tazobactam, tobramycin and amikacin, while 64.4% remained susceptible to gentamicin. All the isolates were susceptible to cefiderocol, colistin, and tigecycline. One ceftazidime/avibactam-resistant isolate carrying bla emerged after prolonged therapy. Genomic analysis confirmed a clonal outbreak of Klebsiella pneumoniae ST512 (≤ 16 SNPs; ≤13 cgMLST allelic differences). Phylogenetic comparison showed that the isolates were genetically close to those from Italy and central Spain. All isolates carried bla within Tn4401b. Three bla plasmid structures were identified: an IncFII(K) plasmid (pHCUKPC3), a ColEST258 variant, and a novel cointegrate plasmid (pHCUKPC3co). The virulence-associated factors identified included yersiniabactin (ybt10/ICEKp4), KL107 capsular type, and O2afg O-antigen. Conclusion: This study documents the wider dissemination of ST512/KPC-3 as a high-risk clone in Spain, characterized by persistence driven by clonal dissemination, selective pressure, and plasmid plasticity. Our findings highlight the need to integrate genomic and plasmidomic surveillance to anticipate resistance evolution and contain high-risk clones.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Clonal dissemination and plasmid plasticity of KPC-3–producing Klebsiella pneumoniae ST512 during a hospital outbreak in Spain

  • Riesgo-Magaña, María
  • Moreno-Mingorance, Albert
  • Bueno, Jessica
  • Arnal, Sara
  • Alvarado, Elena
  • González-López, Juan José
  • Seral, Cristina
Purpose To describe the first outbreak of KPC-3-producing Klebsiella pneumoniae ST512 in Aragón, Spain, and characterize its clinical, microbiological, and genomic features, including plasmid dynamics, resistance mechanisms, and phylogenetic context. Methods Between July 2022 and July 2024, 130 KPC-3-producing K. pneumoniae isolates were recovered from 33 patients during an outbreak at a tertiary-care hospital in Zaragoza. Antimicrobial susceptibility testing and whole-genome sequencing were performed. Phylogenomic (SNP and cgMLST) and plasmid analyses defined clonal relatedness and plasmid structures. Comparative genomics with 985 international ST512/KPC-3 genomes determined phylogeographic relationships. Results Most cases (84.6%) were detected through active surveillance. All the isolates were resistant to β-lactams, ceftolozane/tazobactam, tobramycin and amikacin, while 64.4% remained susceptible to gentamicin. All the isolates were susceptible to cefiderocol, colistin, and tigecycline. One ceftazidime/avibactam-resistant isolate carrying blaKPC−70 emerged after prolonged therapy. Genomic analysis confirmed a clonal outbreak of Klebsiella pneumoniae ST512 (≤ 16 SNPs; ≤13 cgMLST allelic differences). Phylogenetic comparison showed that the isolates were genetically close to those from Italy and central Spain. All isolates carried blaKPC−3 within Tn4401b. Three blaKPC−3 plasmid structures were identified: an IncFII(K) plasmid (pHCUKPC3), a ColEST258 variant, and a novel cointegrate plasmid (pHCUKPC3co). The virulence-associated factors identified included yersiniabactin (ybt10/ICEKp4), KL107 capsular type, and O2afg O-antigen. Conclusion This study documents the wider dissemination of ST512/KPC-3 as a high-risk clone in Spain, characterized by persistence driven by clonal dissemination, selective pressure, and plasmid plasticity. Our findings highlight the need to integrate genomic and plasmidomic surveillance to anticipate resistance evolution and contain high-risk clones.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

No innocent bystanders: pertussis vaccination and evolutionary parallelisms between Bordetella parapertussis and Bordetella pertussis

  • Bouchez, Valérie
  • Landier, Annie
  • Armatys, Nathalie
  • Guillot, Sophie
  • Moreno-Mingorance, Albert
  • Mir-Cros, Alba
  • Martin Gomez, M. Teresa
  • González-López, Juan José
Bordetella parapertussis; Phylogenetic diversity; Vaccine driven evolution, Bordetella parapertussis; Diversidad filogenética; Evolución impulsada por vacunas, Bordetella parapertussis; Diversitat filogenètica; Evolució impulsada per vacunes, Pathogens adapting to the human host and to vaccination-induced immunity may follow parallel evolutionary paths. Bordetella parapertussis (Bpp) contributes significantly to the burden of whooping cough (pertussis) and shares vaccine antigens with Bordetella pertussis (Bp); both pathogens are phylogenetically related and ecological competitors. Bp vaccine antigen-coding genes have accumulated variation, including pertactin (PRN) disruptions, after the introduction of acellular vaccines in the 1990s. We aimed to evaluate evolutionary parallelisms in Bpp, even though pertussis vaccines were designed against Bp. We sequenced 242 Bpp isolates collected in France, the USA and Spain between 1937 and 2019, spanning pre-vaccine and two vaccines eras. We investigated the temporal evolution of Bpp sublineages using a Bayesian approach based on whole-genome SNPs and performed comparative genomic analyses focusing on antigen and virulence gene loci. The most recent common ancestor of all sequenced Bpp isolates was estimated around the year 1877, making it one of the youngest human pathogens, and the Bpp evolutionary rate we estimated (2.12×10−7 substitutions per site per year) was remarkably similar to the one previously reported for Bp (2.24×10−7). PRN antigen deficiency in Bpp was driven by 18 disruptive mutations, including deletion prn:ΔG-1895 estimated to have occurred around 1998 and observed in 73.8 % (149/202) of post-2007 Bpp isolates. In addition, we detected two early (year ~1900) mutations in the bvgA-fhaB intergenic region, which controls multiple virulence factors including the filamentous haemagglutinin antigen. Gene clusters for pertussis toxin and fimbriae showed a surprising lack of gene decay. Our findings suggest early adaptation of Bpp to humans through modulation of the bvgAS regulon, and a rapid adaptation through the loss of PRN expression, representing a late evolutionary parallelism concomitant with acellular vaccination against whooping cough., The French National Reference Center for Whooping Cough and Other Bordetella Infections receives support from Institut Pasteur and Public Health France (Santé publique France, Saint Maurice, France). This work was supported financially by the French Government’s Investissement d’Avenir grants Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases (ANR-10-LABX-62-IBEID) and INCEPTION (ANR-16-CONV-0005) and by the Spanish ‘Ministerio de Economía y Competitividad’ and ‘Instituto de Salud Carlos III’ [grant number FIS PI18/00703], and by the Centro de Investigación Biomédica en Red (CIBER de Enfermedades Infecciosas [grant number CB21/13/00054]). This work was also supported by the CDC’s Advanced Molecular Detection (AMD) programme.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

  • Sola-Campoy, Pedro Juan
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • Larrosa Escartin, María Nieves
  • Gonzalez Lopez, Juan Jose
  • Cañada-Garcia, Javier E.
  • Moure Garcia, Zaira
Carbapenemases; High-risk clones; Whole genome sequencing, Carbapenemasas; Clones de alto riesgo; Secuenciación del genoma completo, Carbapenemases; Clons d'alt risc; Seqüenciació del genoma sencer, Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain. Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC > 0.12 mg/L with immunochromatography, colorimetric tests, carbapenem inactivation, or carbapenem hydrolysis with MALDI-TOF). Prevalence and incidence were calculated according to population denominators. Antibiotic susceptibility testing was performed using the microdilution method (EUCAST). All 403 isolates collected were sequenced for high-resolution single-nucleotide polymorphism (SNP) typing, core genome multilocus sequence typing (cgMLST), and resistome analysis. Results: In total, 377 (93.5%) CP-Kpn and 26 (6.5%) CP-Eco isolates were collected from 62 (87.3%) hospitals in 46 (92%) provinces. CP-Kpn was more prevalent in the blood (5.8%, 50/853) than in the urine (1.4%, 201/14,464). The cumulative incidence for both CP-Kpn and CP-Eco was 0.05 per 100 admitted patients. The main carbapenemase genes identified in CP-Kpn were blaOXA–48 (263/377), blaKPC–3 (62/377), blaVIM–1 (28/377), and blaNDM–1 (12/377). All isolates were susceptible to at least two antibiotics. Interregional dissemination of eight high-risk CP-Kpn clones was detected, mainly ST307/OXA-48 (16.4%), ST11/OXA-48 (16.4%), and ST512-ST258/KPC (13.8%). ST512/KPC and ST15/OXA-48 were the most frequent bacteremia-causative clones. The average number of acquired resistance genes was higher in CP-Kpn (7.9) than in CP-Eco (5.5). Conclusion: This study serves as a first step toward WGS integration in the surveillance of carbapenemase-producing Enterobacterales in Spain. We detected important epidemiological changes, including increased CP-Kpn and CP-Eco prevalence and incidence compared to previous studies, wide interregional dissemination, and increased dissemination of high-risk clones, such as ST307/OXA-48 and ST512/KPC-3., This research was supported by grants from the Instituto de Salud Carlos III (numbers PI18CIII/00030 and PI21CIII/00039). It was also supported by Plan Nacional de I + D + i 2013–2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (grants RD16CIII/0004/0002, RD16/0016/0001, RD16/0016/0003, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0008, RD16/0016/0010, and RD16/0016/0011). Cofinanced by the European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligent Growth 2014–2020. CIBER – Consorcio Centro de Investigación Biomédica en Red (CB21/13/00095, CB21/13/00012, CB21/13/00049, CB21/13/00054, CB21/13/00055, CB21/13/00068, CB21/13/00081, CB21/13/00084, and CB21/13/00099) (CIBERINFEC) and Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU also supported this work.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020–21: outbreak of XRD Shigella sonnei and dissemination of ESBL-producing Shigella flexneri

  • Moreno-Mingorance, Albert
  • Mir Cros, Alba
  • Goterris Bonet, Lidia
  • Rodríguez Garrido, Virginia
  • Sulleiro, Elena
  • Barberà Gracia, Mª Jesús
  • Descalzo Jorro, Vicente
  • Bravo, Albert
  • Roca, Josep
  • González-López, Juan José
  • Pumarola Suñe, Tomàs
  • VIÑADO, BELEN
  • Larrosa, María Nieves
  • Hoyos Mallecot, Yannick
Antimicrobial resistance; Shigella sonnei; Sexually transmitted infection, Resistencia antimicrobiana; Shigella sonnei; Infección de transmisión sexual, Resistència antimicrobiana; Shigella sonnei; Infecció de transmissió sexual, Background Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers. Objectives To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries. Results From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring blaCTX-M-27 and 14% of Shigella flexneri were MDR harbouring blaCTX-M-27. WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM. Conclusions We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens., This work was partially supported by the ‘Ministerio de Economía y Competitividad’, ‘Instituto de Salud Carlos III’, and co-financed by the European Regional Development Fund (ERDF) ‘A Way to Achieve Europe’ (Spanish Network for Research in Infectious Diseases, grant number RD16/0016/0003) and by the Centro de Investigación Biomédica en Red (CIBER de Enfermedades Infecciosas, grant no. CB21/13/00054). A.M.M. is supported by a grant from the ‘Fondo de Investigación Sanitaria’ (Contratos Predoctorales de Formación en Investigación, grant number FI19/00315).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Sola-Campoy, Pedro J.
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • González, Mónica
  • Gracia-Ahufinger, Irene
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Mulet, Xavier
  • Pitart, Cristina|||0000-0002-3083-7915
  • Rivera, Alba|||0000-0002-9709-6162
  • Bou, German|||0000-0001-8837-0062
  • Calvo, Jorge
  • Cantón, Rafael|||0000-0003-1675-3173
  • González-López, Juanjo|||0000-0003-2419-5909
  • Martínez-Martínez, Luis
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oliver, Antonio|||0000-0001-9327-1894
  • Palacios-Baena, Zaira R.|||0000-0002-1713-6807
  • Pascual Hernández, Álvaro|||0000-0002-8672-5891
  • Ruiz-Carrascoso, Guillermo
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Aracil, Belén
  • Pérez-Vázquez, María
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain. Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

No innocent bystanders: pertussis vaccination and evolutionary parallelisms between Bordetella parapertussis and Bordetella pertussis

  • Bouchez, Valérie
  • Landier, Annie
  • Armatys, Nathalie
  • Guillot, Sophie
  • Moreno-Mingorance, Albert
  • Mir-Cros, Alba
  • Martin Gomez, M. Teresa
  • González-López, Juan José
Bordetella parapertussis; Phylogenetic diversity; Vaccine driven evolution, Bordetella parapertussis; Diversidad filogenética; Evolución impulsada por vacunas, Bordetella parapertussis; Diversitat filogenètica; Evolució impulsada per vacunes, Pathogens adapting to the human host and to vaccination-induced immunity may follow parallel evolutionary paths. Bordetella parapertussis (Bpp) contributes significantly to the burden of whooping cough (pertussis) and shares vaccine antigens with Bordetella pertussis (Bp); both pathogens are phylogenetically related and ecological competitors. Bp vaccine antigen-coding genes have accumulated variation, including pertactin (PRN) disruptions, after the introduction of acellular vaccines in the 1990s. We aimed to evaluate evolutionary parallelisms in Bpp, even though pertussis vaccines were designed against Bp. We sequenced 242 Bpp isolates collected in France, the USA and Spain between 1937 and 2019, spanning pre-vaccine and two vaccines eras. We investigated the temporal evolution of Bpp sublineages using a Bayesian approach based on whole-genome SNPs and performed comparative genomic analyses focusing on antigen and virulence gene loci. The most recent common ancestor of all sequenced Bpp isolates was estimated around the year 1877, making it one of the youngest human pathogens, and the Bpp evolutionary rate we estimated (2.12×10−7 substitutions per site per year) was remarkably similar to the one previously reported for Bp (2.24×10−7). PRN antigen deficiency in Bpp was driven by 18 disruptive mutations, including deletion prn:ΔG-1895 estimated to have occurred around 1998 and observed in 73.8 % (149/202) of post-2007 Bpp isolates. In addition, we detected two early (year ~1900) mutations in the bvgA-fhaB intergenic region, which controls multiple virulence factors including the filamentous haemagglutinin antigen. Gene clusters for pertussis toxin and fimbriae showed a surprising lack of gene decay. Our findings suggest early adaptation of Bpp to humans through modulation of the bvgAS regulon, and a rapid adaptation through the loss of PRN expression, representing a late evolutionary parallelism concomitant with acellular vaccination against whooping cough., The French National Reference Center for Whooping Cough and Other Bordetella Infections receives support from Institut Pasteur and Public Health France (Santé publique France, Saint Maurice, France). This work was supported financially by the French Government’s Investissement d’Avenir grants Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases (ANR-10-LABX-62-IBEID) and INCEPTION (ANR-16-CONV-0005) and by the Spanish ‘Ministerio de Economía y Competitividad’ and ‘Instituto de Salud Carlos III’ [grant number FIS PI18/00703], and by the Centro de Investigación Biomédica en Red (CIBER de Enfermedades Infecciosas [grant number CB21/13/00054]). This work was also supported by the CDC’s Advanced Molecular Detection (AMD) programme.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020–21: outbreak of XRD Shigella sonnei and dissemination of ESBL-producing Shigella flexneri

  • Moreno-Mingorance, Albert
  • Mir Cros, Alba
  • Goterris Bonet, Lidia
  • Rodríguez Garrido, Virginia
  • Sulleiro, Elena
  • Barberà Gracia, Mª Jesús
  • Descalzo Jorro, Vicente
  • Bravo, Albert
  • Roca, Josep
  • González-López, Juan José
  • Pumarola Suñe, Tomàs
  • VIÑADO, BELEN
  • Larrosa, María Nieves
  • Hoyos Mallecot, Yannick
Antimicrobial resistance; Shigella sonnei; Sexually transmitted infection, Resistencia antimicrobiana; Shigella sonnei; Infección de transmisión sexual, Resistència antimicrobiana; Shigella sonnei; Infecció de transmissió sexual, Background Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers. Objectives To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries. Results From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring blaCTX-M-27 and 14% of Shigella flexneri were MDR harbouring blaCTX-M-27. WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM. Conclusions We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens., This work was partially supported by the ‘Ministerio de Economía y Competitividad’, ‘Instituto de Salud Carlos III’, and co-financed by the European Regional Development Fund (ERDF) ‘A Way to Achieve Europe’ (Spanish Network for Research in Infectious Diseases, grant number RD16/0016/0003) and by the Centro de Investigación Biomédica en Red (CIBER de Enfermedades Infecciosas, grant no. CB21/13/00054). A.M.M. is supported by a grant from the ‘Fondo de Investigación Sanitaria’ (Contratos Predoctorales de Formación en Investigación, grant number FI19/00315).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

  • Sola-Campoy, Pedro Juan
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • Larrosa Escartin, María Nieves
  • Gonzalez Lopez, Juan Jose
  • Cañada-Garcia, Javier E.
  • Moure Garcia, Zaira
Carbapenemases; High-risk clones; Whole genome sequencing, Carbapenemasas; Clones de alto riesgo; Secuenciación del genoma completo, Carbapenemases; Clons d'alt risc; Seqüenciació del genoma sencer, Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain. Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC > 0.12 mg/L with immunochromatography, colorimetric tests, carbapenem inactivation, or carbapenem hydrolysis with MALDI-TOF). Prevalence and incidence were calculated according to population denominators. Antibiotic susceptibility testing was performed using the microdilution method (EUCAST). All 403 isolates collected were sequenced for high-resolution single-nucleotide polymorphism (SNP) typing, core genome multilocus sequence typing (cgMLST), and resistome analysis. Results: In total, 377 (93.5%) CP-Kpn and 26 (6.5%) CP-Eco isolates were collected from 62 (87.3%) hospitals in 46 (92%) provinces. CP-Kpn was more prevalent in the blood (5.8%, 50/853) than in the urine (1.4%, 201/14,464). The cumulative incidence for both CP-Kpn and CP-Eco was 0.05 per 100 admitted patients. The main carbapenemase genes identified in CP-Kpn were blaOXA–48 (263/377), blaKPC–3 (62/377), blaVIM–1 (28/377), and blaNDM–1 (12/377). All isolates were susceptible to at least two antibiotics. Interregional dissemination of eight high-risk CP-Kpn clones was detected, mainly ST307/OXA-48 (16.4%), ST11/OXA-48 (16.4%), and ST512-ST258/KPC (13.8%). ST512/KPC and ST15/OXA-48 were the most frequent bacteremia-causative clones. The average number of acquired resistance genes was higher in CP-Kpn (7.9) than in CP-Eco (5.5). Conclusion: This study serves as a first step toward WGS integration in the surveillance of carbapenemase-producing Enterobacterales in Spain. We detected important epidemiological changes, including increased CP-Kpn and CP-Eco prevalence and incidence compared to previous studies, wide interregional dissemination, and increased dissemination of high-risk clones, such as ST307/OXA-48 and ST512/KPC-3., This research was supported by grants from the Instituto de Salud Carlos III (numbers PI18CIII/00030 and PI21CIII/00039). It was also supported by Plan Nacional de I + D + i 2013–2016, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (grants RD16CIII/0004/0002, RD16/0016/0001, RD16/0016/0003, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0008, RD16/0016/0010, and RD16/0016/0011). Cofinanced by the European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligent Growth 2014–2020. CIBER – Consorcio Centro de Investigación Biomédica en Red (CB21/13/00095, CB21/13/00012, CB21/13/00049, CB21/13/00054, CB21/13/00055, CB21/13/00068, CB21/13/00081, CB21/13/00084, and CB21/13/00099) (CIBERINFEC) and Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU also supported this work.